烟台东诚药业集团股份有限公司关于控股子公司获得药物临床试验批准通知书的公告

Group 1 - The core announcement is that Yantai Dongcheng Pharmaceutical Group Co., Ltd.'s subsidiary, Yantai Lanacheng Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of the drug 177Lu-LNC1009 injection, which targets advanced malignant solid tumors [1][2] - The drug 177Lu-LNC1009 is a dual-target radioactive therapy aimed at FAP-positive and integrin αvβ3-positive patients, showing potential for improved tumor targeting and treatment efficacy [2][3] - The total research and development investment for 177Lu-LNC1009 has reached approximately 13.579 million yuan [2] Group 2 - The company announced that its full subsidiary, Nanjing Jiangyuan Andico Positron Research and Development Co., Ltd., has had its product, Technetium-99m (99mTc) Tetrofosmin injection, included in the National Medical Insurance Directory for 2025, which is expected to enhance market accessibility and promote sales [4] - The inclusion in the medical insurance directory will officially take effect on January 1, 2026, and is not expected to have a significant impact on the company's financial performance in the short term [4]